share_log

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors With RAS Mutations

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors With RAS Mutations

免疫系統公司宣佈FDA批准了IMM-1-104治療RAS突變的晚期實體腫瘤的1/2a期臨牀試驗的IND申請
Benzinga Real-time News ·  2022/09/30 06:52

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

免疫系統公司宣佈FDA批准了IMM-1-104治療RAS突變的晚期實體腫瘤的1/2a期臨牀試驗的IND申請

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論